13G Filing: Empery Asset Management, LP and Eyegate Pharmaceuticals Inc (EYEG)

Page 4 of 9 – SEC Filing

 

1

NAMES OF REPORTING PERSONS

Martin D. Hoe

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) ¨

(b) ¨

3 SEC USE ONLY
4

CITIZENSHIP OR PLACE OF ORGANIZATION

United States

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
5

SOLE VOTING POWER

6

SHARED VOTING POWER

1,500,000 shares of Common Stock

1,500,000 shares of Common Stock issuable upon exercise
of Warrants (See Item 4)*

7

SOLE DISPOSITIVE POWER

8

SHARED DISPOSITIVE POWER

1,500,000 shares of Common Stock

1,500,000 shares of Common Stock issuable upon exercise
of Warrants (See Item 4)*

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

1,500,000 shares of Common Stock

1,500,000 shares of Common Stock issuable upon exercise
of Warrants (See Item 4)*

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

9.22% (See Item 4)*

12

TYPE OF REPORTING PERSON

IN

* As more fully described in Item 4, the
Warrants are subject to a 4.99% blocker, and the percentage set forth in row (11) gives effect to such blockers. However, as more
fully described in Item 4, the securities reported in rows (6), (8) and (9) show the number of shares of Common Stock that would
be issuable upon full exercise of such reported securities and do not give effect to such blockers. Therefore, the actual number
of shares of Common Stock beneficially owned by such Reporting Person, after giving effect to such blockers, is less than the
number of securities reported in rows (6), (8) and (9).

Follow Kiora Pharmaceuticals Inc (NASDAQ:KPRX)